Valuation: Insmed Incorporated

Market Cap 2.62TCr 2.35TCr 2.17TCr 1.97TCr 3.72TCr 2,45800Cr 3.83TCr 26TCr 10TCr 1,31700Cr 9.84TCr 9.63TCr 4,16300Cr P/E 2026 *
-72.9x
P/E 2027 * 161x
Enterprise Value 2.57TCr 2.3TCr 2.12TCr 1.93TCr 3.65TCr 2,41000Cr 3.75TCr 25TCr 10TCr 1,29100Cr 9.64TCr 9.44TCr 4,08100Cr EV / Sales 2026 *
13.8x
EV / Sales 2027 * 8.44x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day+2.92%
1 week+14.41%
Current month+6.14%
1 month+18.78%
3 months-11.32%
6 months+17.90%
Current year-31.34%
1 week 106.16
Extreme 106.16
119.85
1 month 92.62
Extreme 92.625
119.85
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 11.31
Extreme 11.31
212.75
Manager TitleAgeSince
Chief Executive Officer 57 10/09/2012
Chief Tech/Sci/R&D Officer 62 19/12/2019
Chief Operating Officer 57 14/11/2019
Director TitleAgeSince
Chairman 75 16/06/2009
Chairman 57 08/11/2018
Director/Board Member 72 29/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
19/10/26 Free

Director

6,139 0.0028%
19/10/26 Free

Director

6,139 0.0028%
09/09/26 Sell

Director

-25,000 0.0114%
Change 5-day change 1-year change 3-year change Capi.($)
+2.92%+14.41%-37.74%+403.12% 2.62TCr
+0.01%+11.10%+60.83%+70.43% 6.83TCr
+1.22%+9.56%+15.97%+90.23% 6.03TCr
+0.24%+1.35%+23.78%+97.55% 5.59TCr
+1.60%+19.44%+28.80%+112.95% 4.84TCr
-1.32%+4.78%+29.15%+40.40% 4.53TCr
-3.54%-0.60%+207.76%+879.50% 4.18TCr
-3.33%+6.90%+22.78%+48.07% 3.45TCr
-2.19%-3.71%+90.94%+66.33% 3.38TCr
-1.77%+0.83%+46.57%-0.16% 2.6TCr
Average -0.62%+6.30%+48.88%+180.84% 4TCr
Weighted average by Cap. -0.46%+5.80%+49.76%+168.44%

Financials

2026 *2027 *
Net sales 186.13Cr 166.93Cr 153.84Cr 139.71Cr 264.41Cr 17TCr 271.79Cr 1.84TCr 733.89Cr 9.35TCr 698.54Cr 683.73Cr 30TCr 299.24Cr 268.36Cr 247.32Cr 224.61Cr 425.09Cr 28TCr 436.95Cr 2.96TCr 1.18TCr 15TCr 1.12TCr 1.1TCr 48TCr
Net income -36Cr -32Cr -30Cr -27Cr -51Cr -3.35TCr -52Cr -353.63Cr -140.89Cr -1.8TCr -134.11Cr -131.26Cr -5.67TCr 17Cr 15Cr 14Cr 13Cr 24Cr 1.57TCr 24Cr 165.68Cr 66Cr 840.99Cr 63Cr 61Cr 2.66TCr
Net Debt -51Cr -46Cr -43Cr -39Cr -73Cr -4.82TCr -75Cr -509.11Cr -202.84Cr -2.58TCr -193.07Cr -188.98Cr -8.17TCr -95Cr -85Cr -78Cr -71Cr -134.81Cr -8.9TCr -138.57Cr -939.13Cr -374.17Cr -4.77TCr -356.15Cr -348.6Cr -15TCr
Projected Income Statement - Annual - Insmed Incorporated
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
10/26/10 $119.49 +2.92% 33,46,741
09/26/09 $116.10 +1.48% 26,68,854
06/26/06 $114.41 +5.19% 33,79,993
05/26/05 $108.76 -1.13% 26,16,308
04/26/04 $110.00 +5.32% 49,44,543
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Insmed Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
119.49USD
Average target price
194.18USD
Spread / Average Target
+62.51%
  1. Stock Market
  2. Stocks
  3. INSM Stock